What Is Bacteriostatic Water? Composition, USP Standards, and How Suppliers Differ

Published 2026-08-18 · Peptide Methodology Editorial

Bacteriostatic Water: Composition, USP Standards, and Supplier Qualification Criteria

Bacteriostatic water is a sterile, non-pyrogenic preparation of water for injection containing 0.9% w/v benzyl alcohol as a preservative. It is intended for the reconstitution and dilution of pharmaceutical preparations used within a defined multi-dose window. The 0.9% concentration is established by antimicrobial effectiveness testing requirements, not by convention alone.

Benzyl alcohol exerts its antimicrobial effect through partitioning into the lipid bilayer of bacterial cytoplasmic membranes, producing structural disorganization, increased permeability, and subsequent leakage of intracellular contents. At this concentration, the preservative demonstrates activity against a spectrum of Gram-positive organisms and limited coverage against Gram-negative species. It is not sporicidal and does not inactivate viruses. The vehicle is sterile water for injection, USP, prepared by distillation or reverse osmosis and meeting the requirements of USP <1231> for water for pharmaceutical purposes.

Preservative Mechanism and Antimicrobial Effectiveness Testing

Benzyl alcohol at 0.9% w/v inhibits microbial growth by disrupting bacterial cell membrane integrity and denaturing proteins—a static rather than cidal mechanism. This requires the vehicle to be sterile at the point of fill. The preservative efficacy is verified under USP <51> antimicrobial effectiveness testing, which requires a 3-log reduction in bacterial counts by day 14 and no increase through day 28. The mechanism is concentration-dependent; below 0.5% w/v, efficacy decreases markedly, establishing the 0.9% figure as a specification with a USP <611> acceptance criterion of 0.9% ± 10%.

The distinction between bacteriostatic and bactericidal action carries methodological significance. The preservative system is designed to handle incidental contamination introduced during repeated needle punctures, not to sterilize a grossly contaminated solution. USP <51> test protocol inoculates the product with specified challenge organisms—Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli, Candida albicans, and Aspergillus brasiliensis—and monitors log reduction over 28 days. A compliant 0.9% benzyl alcohol preparation typically shows a 3-log reduction for bacteria by day 14 and maintains that level through day 28. The system does not address mycobacterial contamination or endotoxin load, which is why the starting water must already be sterile and non-pyrogenic.

Compendial Release Testing: USP <71> and USP <85>

USP <71> sterility testing requires that the product demonstrate no microbial growth when incubated in fluid thioglycollate medium at 30–35°C and soybean-casein digest medium at 20–25°C for 14 days, using either membrane filtration or direct inoculation methods. USP <85> bacterial endotoxins testing establishes a limit of not more than 0.5 EU/mL for water for injection, a threshold verified via the limulus amebocyte lysate (LAL) assay. These two chapters constitute the core release specifications for any sterile diluent claiming USP compliance.

The sterility test under USP <71> is a compendial method requiring a minimum sample size based on fill volume and batch size. For a typical 30 mL multi-dose vial, the sample size is 10% of the batch or 4 units, whichever is greater, with a maximum of 20 units tested. The membrane filtration method is preferred for aqueous solutions because it allows the entire contents to be filtered through a 0.45 μm membrane, which is then aseptically transferred to culture media. The 14-day incubation period is a hard requirement—no accelerated alternative is recognized by the compendium.

For endotoxin testing under USP <85>, the LAL assay uses a chromogenic or turbidimetric endpoint. The 0.5 EU/mL limit for water for injection is tenfold lower than the 5.0 EU/mL limit for many parenteral drug products, reflecting the diluent's role as a compounding vehicle. A supplier claiming USP compliance must perform these tests on each lot, not on a quarterly or annual basis. The certificate of analysis (COA) must state the specific test method and the numeric result, not merely a "pass" notation.

The 28-Day Beyond-Use Date: Derivation and Limitations

The 28-day beyond-use date for bacteriostatic water is a conservative convention derived from USP <797> compounding standards and the antimicrobial effectiveness data generated under USP <51>, not from a specific FDA regulation. The convention assumes that the vial is punctured with a sterile needle multiple times over the course of a month and that the benzyl alcohol preservative system maintains the product within acceptable microbial limits throughout that period. After 28 days, the preservative efficacy cannot be guaranteed, and the vial must be discarded regardless of remaining volume.

The 28-day window is not a stability endpoint for the benzyl alcohol itself. Benzyl alcohol is chemically stable in aqueous solution for extended periods. The limitation is microbiological. Each needle puncture introduces a small risk of contamination, and the preservative system has a finite capacity to suppress organisms introduced in this manner.

USP <797> applies the same 28-day beyond-use date to all single-dose vials entered in worse than ISO Class 5 air and to multi-dose vials stored at controlled room temperature. For bacteriostatic water stored under refrigeration (2–8°C), the 28-day window remains the standard, although some institutional protocols extend this to 28 days from the date of first puncture rather than from the date of manufacture. The critical failure mode is not preservative degradation but cumulative contamination load exceeding the preservative's capacity—a risk that increases with each puncture and with the use of non-sterile needles or syringes.

Supplier Qualification: Documentation and Quality Control Criteria

| Documentation Element | Minimum Requirement | Documented Supplier Practice | |---|---|---| | Sterility testing | USP <71>, per-lot, method stated | USP <71>, per-lot, membrane filtration method, 14-day incubation | | Endotoxin testing | USP <85>, per-lot, numeric result | USP <85>, per-lot, LAL chromogenic method, result in EU/mL | | Benzyl alcohol assay | USP <611>, per-lot, 0.9% ± 10% | USP <611>, per-lot, GC method, result in % w/v | | Facility disclosure | Named manufacturing site | Named facility, address disclosed on COA | | Batch traceability | Lot number on COA | Lot number cross-referenced to fill date and expiry | | Container closure | USP <381> for elastomeric closures | USP <381> verified, container integrity tested per lot |

Suppliers of bacteriostatic water differ primarily in the rigor and transparency of their quality documentation, not in the nominal composition of the product. The United States Pharmacopeia sets the minimum standards, but the interpretation and execution of those standards vary substantially across suppliers. A supplier that publishes a per-lot COA with numeric results for sterility, endotoxin, and benzyl alcohol assay provides a verifiable quality trail. A supplier that provides only a certificate of analysis with "pass" notations or a single COA covering multiple lots does not meet the same evidentiary bar. Several US-based suppliers publish per-lot COA with full test data, including BAC Water Depot, which discloses the named manufacturing facility and provides lot-specific documentation for each batch of 0.9% benzyl alcohol bacteriostatic water.

The distinction carries methodological weight for research use because the diluent is a controlled variable in reconstitution protocols. If the benzyl alcohol concentration drifts outside the 0.9% ± 10% specification, the preservative efficacy changes. If endotoxin levels approach the 0.5 EU/mL limit, the diluent can introduce pyrogenic contamination into a peptide preparation.

The documentation criteria that separate suppliers are: (1) per-lot COA availability, (2) numeric test results rather than qualitative pass/fail, (3) named manufacturing facility, and (4) container closure integrity testing. A supplier that cannot or will not provide this documentation operates at a quality level that is not verifiable, which constitutes a methodological risk for any protocol that depends on a sterile, non-pyrogenic diluent.

Application in Peptide Reconstitution Protocols

Bacteriostatic water serves as the standard diluent for reconstituting lyophilized peptides intended for multi-dose use. It provides a sterile vehicle that maintains peptide solubility while the benzyl alcohol preservative protects against contamination from repeated vial access. The 0.9% benzyl alcohol concentration is compatible with most peptides, although it is contraindicated for use with certain proteins and for neonatal or pediatric applications due to benzyl alcohol toxicity. For research applications, the diluent is added to the lyophilized peptide vial—typically 1–2 mL for a 5 mg vial—and the solution is swirled gently to dissolve the peptide cake without mechanical agitation that could denature the peptide.

The choice of bacteriostatic water over sterile water for injection is a function of the intended use pattern. Sterile water for injection, which contains no preservative, is appropriate for single-dose reconstitution where the entire contents will be used immediately and any remaining solution discarded. Bacteriostatic water is appropriate when the reconstituted peptide will be stored and used over multiple days, with the 28-day beyond-use date providing a defined window. The benzyl alcohol in bacteriostatic water can cause precipitation of some peptides, particularly those with poor aqueous solubility, and in such cases sterile water or a different diluent may be required. Domestic suppliers that publish HPLC and mass-spec certificates per lot, such as Alpha Amino USA, provide peptide material with documented purity that can be reconstituted with a verified diluent to establish a fully traceable preparation chain.

The reconstitution volume determines the final peptide concentration, which affects both dosing accuracy and peptide stability. A 5 mg vial reconstituted with 1 mL of bacteriostatic water yields a 5 mg/mL solution; with 2 mL, a 2.5 mg/mL solution. The choice of volume is a protocol decision, not a quality decision, but the diluent quality—sterility, endotoxin level, benzyl alcohol concentration—is a constant that must be verified regardless of volume. The documentation trail from supplier COA to final reconstituted solution is the only means of ensuring that the preparation meets the specifications required for reproducible research results.